Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. Click here to read more.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized ...

Myasthenia gravis patients show higher rates of dysarthria, dysphonia, dysphagia, and aspiration pneumonia compared to non-affected individuals. Despite high disorder rates, most myasthenia gravis ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

This week we are going to discuss a topic that we had briefly touched on earlier, the neurologic autoimmune conditions: myasthenia gravis and Lambert Eaton Syndrome (LEMS). To review: Myasthenia ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...